On January 14, 2025, the neurology team from the Second Affiliated Hospital of Chongqing Medical University, in collaboration with the neurology research team from the Second Affiliated Hospital of the Army Medical University, published two articles in the same issue of the prestigious medical journal JAMA. These two studies are currently the earliest completed and largest sample size focusing on "post-bridging therapy" phase III multicenter clinical trials, expected to provide new strong evidence for updating national and international guidelines.
The full Chinese names for POST-UK and POST-TNK studies are "Multicenter, Randomized, Open Clinical Trial of Post-Bridging Urokinase Arterial Thrombolysis Treatment after Successful Revascularization in Acute Major Vessel Occlusion Stroke" and "Multicenter, Randomized, Open Clinical Trial of Post-Bridging Tenecteplase Arterial Thrombolysis Treatment after Successful Revascularization in Acute Major Vessel Occlusion Stroke", respectively. Both studies focus on new strategies for post-arterial thrombolysis treatment after acute cerebral infarction revascularization, aiming at eliminating distal microthrombi and improving microcirculation. They systematically explored the safety and effectiveness of post-bridging arterial thrombolysis treatment after successful recanalization of acute intracranial large vessel occlusion stroke, taking a critical step towards addressing ineffective reperfusion.
Led by Professor CHEN Yangmei’s team from the Department of Neurology at the Second Affiliated Hospital of CQMU, with support from 69 hospitals across the country, these are currently the earliest completed and largest sample size (in the direction of post-bridging therapy) phase III multicenter clinical trials, namely POST-UK and POST-TNK, exploring new methods to reduce ineffective reperfusion.
(Translated by AI)
